Disability Progression in Multiple Sclerosis Patients using Early First-line Treatments - Centre de Recherche en Neurosciences de Lyon Accéder directement au contenu
Article Dans Une Revue European Journal of Neurology Année : 2022

Disability Progression in Multiple Sclerosis Patients using Early First-line Treatments

Résumé

BACKGROUND: Therapeutic management of relapsing-remitting multiple sclerosis (RRMS) has evolved towards early treatment. The objective was to assess the impact of early treatment initiation on disability progression among RRMS first-line treated patients. METHODS: This study included all incident RRMS cases starting interferon or glatiramer acetate for the first time from 1996/01/01 to 2012/31/12 (N=5,279) from ten MS expert OFSEP centers (Observatoire Français de la Sclérose en Plaques). The delay from treatment start to attain an irreversible Expanded Disability Status Scale score of 3.0 were compared between "Early" group (N= 1,882; treated within 12 months following MS clinical onset) and "Later" group using propensity score weighted Kaplan-Meier methods, overall and stratified by age. RESULTS: Overall, the restricted mean time before reaching EDSS 3.0 (RMST) from treatment start was 11 years and two months for patients treated within the year following MS clinical onset and 10 years and seven months for patients treated later. Thus, early treated patients gained 7 months (95% CI: [4-11] months) in the time to reach EDSS 3.0 compared to patients treated later (treatment start delayed by 28 months). The difference in RMST was respectively six months (95% CI: [1-10] months) and 14 months (95% CI: [4-24] months) in the "≤40 years" age group and in the ">40 years" age group, in favour of early group. . CONCLUSIONS: Early treatment initiation resulted in a significant reduction of disability progression among patients with RRMS, and also among older patients.
Fichier principal
Vignette du fichier
Lefort - 2022 - Disability progression in multiple sclerosis patients using early first_u2010line.pdf (1.54 Mo) Télécharger le fichier
Lefort_ene15422-sup-0001-appendixs1.pdf (357.39 Ko) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03690316 , version 1 (16-06-2022)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Mathilde Lefort, Sandra Vukusic, Romain Casey, Gilles Edan, Emmanuelle Leray. Disability Progression in Multiple Sclerosis Patients using Early First-line Treatments. European Journal of Neurology, 2022, 29 (9), pp.2761-2771. ⟨10.1111/ene.15422⟩. ⟨hal-03690316⟩
84 Consultations
157 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More